GSK's first-quarter results failed to meet expectations and will reduce more anti-cancer drug inputs

Compileriver

A few days ago, GSK released its first quarter financial report.

GSK experienced several major oncology setbacks in the first quarter.

GSK revealed in the first quarter report that due to the priority of its product portfolio, the company will abandon the phase I development plan of DMD's hematopoietic prostaglandin D2 synthase inhibitor GSK3439171 and the oncology drug candidate GSK3537142 in cooperation with Immunocore.

Immunocore signed an agreement with GSK as early as 2013 to sell its ImmTAC molecule, which is designed to change the direction of the immune system to recognize and kill cancer cells.

Hal Barron was once seen by GSK as a hope to revive oncology, but he suffered a series of setbacks, including mid-term failure, which led the company to abandon its induction of T cell costimulation (ICOS) agonist feladilimab earlier this month.

In addition, the future CEO of GSK Emma Walmsley will focus on the spin-off plan for the consumer healthcare business next year.

Reference source: The pressure builds for Emma Walmsley as GlaxoSmithKline misses Q1 projection, drops more cancer drugs